Tag: Big Pharma
-
AbbVie’s Etentamig Cuts Progression or Death Risk by 60% in Phase 3 Multiple Myeloma Trial
AbbVie’s etentamig met both primary endpoints in the Phase 3 CERVINO trial, achieving a 74.0% objective response rate and reducing the risk of progression or death by 60% versus standard available therapies.
-
How Etentamig Redirects T Cells in Multiple Myeloma
Etentamig is a BCMA × CD3 bispecific T-cell engager designed with bivalent BCMA binding, low-affinity CD3 engagement and retained FcRn binding to redirect T cells against multiple myeloma cells.
-
GSK Licenses HUTCHMED’s HMPL-A830 in a Deal Worth Up to $1.295 Billion
GSK licensed HUTCHMED’s preclinical HMPL-A830 for up to $1.295 billion, gaining ex-Greater China rights to a KRAS-EGFR antibody-targeted therapy conjugate designed to combine EGFR-guided delivery with intracellular KRAS inhibition.
-
How HMPL-A830 Delivers KRAS Inhibition Through EGFR-Targeted Therapy
HMPL-A830 is a preclinical KRAS-EGFR antibody-targeted therapy conjugate designed to bind EGFR-expressing tumor cells, undergo internalization and release a KRAS inhibitor payload intracellularly while also suppressing EGFR signaling.
-
Novartis’ Pelacarsen Fails Phase 3 Lp(a)HORIZON Despite Lowering Lp(a)
Novartis and Ionis reported that pelacarsen lowered Lp(a) but failed to significantly reduce 4-point MACE in the Phase 3 Lp(a)HORIZON trial, raising new questions about the clinical validity of Lp(a) lowering.
-
Why Lowering Lp(a) Wasn’t Enough: What Pelacarsen’s Phase 3 Failure Means
Pelacarsen targets LPA mRNA to reduce apo(a) production and circulating Lp(a), but the Phase 3 Lp(a)HORIZON result showed that molecular target engagement did not translate into fewer major cardiovascular events.
-
Novartis Remibrutinib Delivers Two Phase 3 Wins in Relapsing Multiple Sclerosis
Novartis reported positive Phase 3 results for remibrutinib in both REMODEL-1 and REMODEL-2, with significant reductions in annualized relapse rate versus teriflunomide and no liver safety signal reported across the two studies.
-
How Remibrutinib May Control Multiple Sclerosis Through BTK Inhibition
Remibrutinib inhibits Bruton’s tyrosine kinase in B cells and myeloid cells, suppressing downstream immune signaling without directly depleting B cells. This mechanism differentiates BTK inhibitors from anti-CD20 therapies and may influence both peripheral inflammation and CNS neuroinflammation in multiple sclerosis.
-
Roche and Eli Lilly Win FDA Clearance for Alzheimer’s Blood Test
Roche and Eli Lilly received FDA clearance for Elecsys pTau217, a single-biomarker blood test designed to assess Alzheimer’s-related amyloid pathology.
-
Genentech Bets $2.3 Billion on Hanmi’s Muscle-Preserving Obesity Drug
Genentech licensed Hanmi’s HM17321 in a deal worth up to $2.3 billion, adding a non-incretin obesity candidate designed to reduce fat while preserving muscle.